Head to Head Contrast: ProKidney (NASDAQ:PROK) versus Crinetics Pharmaceuticals (NASDAQ:CRNX)
by Danessa Lincoln · The Markets DailyProKidney (NASDAQ:PROK – Get Free Report) and Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.
Volatility and Risk
ProKidney has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Institutional & Insider Ownership
51.6% of ProKidney shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares ProKidney and Crinetics Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $890,000.00 | 580.36 | -$68.99 million | ($0.53) | -3.23 |
| Crinetics Pharmaceuticals | $7.70 million | 458.46 | -$465.32 million | ($5.13) | -6.53 |
ProKidney has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ProKidney and Crinetics Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -8,131.50% | N/A | -21.39% |
| Crinetics Pharmaceuticals | -2,747.18% | -43.96% | -39.61% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for ProKidney and Crinetics Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 2 | 1 | 4 | 1 | 2.50 |
| Crinetics Pharmaceuticals | 1 | 0 | 8 | 1 | 2.90 |
ProKidney currently has a consensus price target of $7.40, suggesting a potential upside of 332.75%. Crinetics Pharmaceuticals has a consensus price target of $76.13, suggesting a potential upside of 127.37%. Given ProKidney’s higher probable upside, equities research analysts plainly believe ProKidney is more favorable than Crinetics Pharmaceuticals.
Summary
ProKidney beats Crinetics Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.